Marie Isabelle Cremers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marie Isabelle Cremers has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
A. L. Alves
1 shared publicationA. P. Oliveira
1 shared publicationAna Luísa Alves
1 shared publicationAna Margarida Vieira
1 shared publicationAna Paula Oliveira
1 shared publicationAnthea Pisani
1 shared publication
Latest Publications
- Open Access
- 28 April 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Meta-Analysis
- Vol. 8 (2) , 41-47
European Specialty Examination in Gastroenterology and Hepatology examination — improving education in gastroenterology and hepatology
The Federation of Royal Colleges, the British Society of Gastroenterology (BSG) and the European Section and Board of Gastroenterology and Hepatology developed the European Specialty Examination in Gastroenterology and Hepatology (ESEGH) from the United Kingdom Specialty Certificate Examination, which was the original examination. Since 2018 the Specialty Certificate Examination and the ESEGH were combined into a single exam, identical across Europe and the rest of the world. The ESEGH is mandated in 4 countries (United Kingdom, Switzerland, The Netherlands and Malta) and the number of entries increased from 50 in 2014 to 490 in 2019. Candidates from countries were the ESEGH is not mandated are sitting the Exam, showing us they realize the enormous interest of holding a certificate for knowledge in their Curriculum. We also have an increasing number of candidates from countries outside Europe.
- 28 April 2020
- Published by Baishideng Publishing Group Inc. in World Journal of Meta-Analysis
- Vol. 8 (2) , 41-47
Open AccessEuropean Specialty Examination in Gastroenterology and Hepatology examination — improving education in gastroenterology and hepatology
The Federation of Royal Colleges, the British Society of Gastroenterology (BSG) and the European Section and Board of Gastroenterology and Hepatology developed the European Specialty Examination in Gastroenterology and Hepatology (ESEGH) from the United Kingdom Specialty Certificate Examination, which was the original examination. Since 2018 the Specialty Certificate Examination and the ESEGH were combined into a single exam, identical across Europe and the rest of the world. The ESEGH is mandated in 4 countries (United Kingdom, Switzerland, The Netherlands and Malta) and the number of entries increased from 50 in 2014 to 490 in 2019. Candidates from countries were the ESEGH is not mandated are sitting the Exam, showing us they realize the enormous interest of holding a certificate for knowledge in their Curriculum. We also have an increasing number of candidates from countries outside Europe.
- 9 June 2014
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 7 (5) , 206-216
Management of variceal and nonvariceal upper gastrointestinal bleeding in patients with cirrhosis
Acute upper gastrointestinal haemorrhage remains the most common medical emergency managed by gastroenterologists. Causes of upper gastrointestinal bleeding (UGIB) in patients with liver cirrhosis can be grouped into two categories: the first includes lesions that arise by virtue of portal hypertension, namely gastroesophageal varices and portal hypertensive gastropathy; and the second includes lesions seen in the general population (peptic ulcer, erosive gastritis, reflux esophagitis, Mallory–Weiss syndrome, tumors, etc.). Emergency upper gastrointestinal endoscopy is the standard procedure recommended for both diagnosis and treatment of UGIB. The endoscopic treatment of choice for esophageal variceal bleeding is band ligation of varices. Bleeding from gastric varices is treated by injection with cyanoacrylate. Treatment with vasoactive drugs as well as antibiotic treatment is started before or at the same time as endoscopy. Bleeding from portal hypertensive gastropathy is less frequent, usually chronic and treatment options include β-blocker therapy, injection therapy and interventional radiology. The standard of care of UGIB in patients with cirrhosis includes careful resuscitation, preferably in an intensive care setting, medical and endoscopic therapy, early consideration for placement of transjugular intrahepatic portosystemic shunt and, sometimes, surgical therapy or hepatic transplant.
- 9 June 2014
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 7 (5) , 206-216
Management of variceal and nonvariceal upper gastrointestinal bleeding in patients with cirrhosis
Acute upper gastrointestinal haemorrhage remains the most common medical emergency managed by gastroenterologists. Causes of upper gastrointestinal bleeding (UGIB) in patients with liver cirrhosis can be grouped into two categories: the first includes lesions that arise by virtue of portal hypertension, namely gastroesophageal varices and portal hypertensive gastropathy; and the second includes lesions seen in the general population (peptic ulcer, erosive gastritis, reflux esophagitis, Mallory–Weiss syndrome, tumors, etc.). Emergency upper gastrointestinal endoscopy is the standard procedure recommended for both diagnosis and treatment of UGIB. The endoscopic treatment of choice for esophageal variceal bleeding is band ligation of varices. Bleeding from gastric varices is treated by injection with cyanoacrylate. Treatment with vasoactive drugs as well as antibiotic treatment is started before or at the same time as endoscopy. Bleeding from portal hypertensive gastropathy is less frequent, usually chronic and treatment options include β-blocker therapy, injection therapy and interventional radiology. The standard of care of UGIB in patients with cirrhosis includes careful resuscitation, preferably in an intensive care setting, medical and endoscopic therapy, early consideration for placement of transjugular intrahepatic portosystemic shunt and, sometimes, surgical therapy or hepatic transplant.
- Open Access
- 21 August 2012
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 27 (9) , 1411-1412
Metabolic syndrome, synchronous gastric and colorectal neoplasms: An ominous triad
- 21 August 2012
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 27 (9) , 1411-1412
Open AccessMetabolic syndrome, synchronous gastric and colorectal neoplasms: An ominous triad
- 19 September 2009
- Vol. 56 (93) , 989-91
A comparative study of two methods of colonic cleansing before colonoscopy.
Good colonic preparation is essential to perform a complete and safe colonoscopy. The preparation used in the Endoscopy Unit was adopted after testing it against the classic 4-liter polyethylene glicol (PEG) preparation (Klean-Prep). Recently a new 3-liter PEG preparation was commercialised in Portugal, Endo-Falk, which appeared to be simpler and effective. The present study compared the preparation we usually use (a combination of 4 tablets of bisacodyl with 2-liter PEG and enemas) with this new preparation. we enrolled 305 patients in 2 groups. Group 1 was given our usual preparation, as described above and group 2 was given the new 3-liter preparation, Endo-Falk. All patients were ambulatory, and only patients undergoing total colonoscopies were included. Patients with benign or malignant stenosis and patients who had previously undergone colorectal resection were excluded. Preparation was graded as good when there were no stools and little liquid in the colon, fair when there were stools or liquid that could be aspirated and did not obscure the mucosa and bad when stools or excess liquid prevented an adequate view of the surface or precluded polipectomy. The present study included 164 male and 141 female patients, with a mean age of 61.3 years (no difference between the demographic data). In group 1 the preparation was good in 57.5%, fair in 28.5% and bad in 14% of patients and in group 2 the preparation was good in 33.1%, fair in 48.9% and bad in 18% (p < 0.001). Colonoscopies were complete in 89.9% of all patients. The usual preparation was better than the new 3-liter PEG solution.
- 19 September 2009
- Vol. 56 (93) , 989-91
A comparative study of two methods of colonic cleansing before colonoscopy.
Good colonic preparation is essential to perform a complete and safe colonoscopy. The preparation used in the Endoscopy Unit was adopted after testing it against the classic 4-liter polyethylene glicol (PEG) preparation (Klean-Prep). Recently a new 3-liter PEG preparation was commercialised in Portugal, Endo-Falk, which appeared to be simpler and effective. The present study compared the preparation we usually use (a combination of 4 tablets of bisacodyl with 2-liter PEG and enemas) with this new preparation. we enrolled 305 patients in 2 groups. Group 1 was given our usual preparation, as described above and group 2 was given the new 3-liter preparation, Endo-Falk. All patients were ambulatory, and only patients undergoing total colonoscopies were included. Patients with benign or malignant stenosis and patients who had previously undergone colorectal resection were excluded. Preparation was graded as good when there were no stools and little liquid in the colon, fair when there were stools or liquid that could be aspirated and did not obscure the mucosa and bad when stools or excess liquid prevented an adequate view of the surface or precluded polipectomy. The present study included 164 male and 141 female patients, with a mean age of 61.3 years (no difference between the demographic data). In group 1 the preparation was good in 57.5%, fair in 28.5% and bad in 14% of patients and in group 2 the preparation was good in 33.1%, fair in 48.9% and bad in 18% (p < 0.001). Colonoscopies were complete in 89.9% of all patients. The usual preparation was better than the new 3-liter PEG solution.
- 31 December 2006
- Published by Elsevier in Digestive and Liver Disease
- Vol. 38 (12) , 912-917
Colonoscopies in Portuguese District Hospitals: A multicentric transverse study
- 31 December 2006
- Published by Elsevier in Digestive and Liver Disease
- Vol. 38 (12) , 912-917
Colonoscopies in Portuguese District Hospitals: A multicentric transverse study
- Open Access
- 1 February 2002
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 34 (2) , 177
Portal Hypertensive Gastropathy: Treatment with Corticosteroids
Portal hypertensive gastropathy (PHG) has been recognised as an increasingly important source of bleeding in cirrhotic patients in whom an esophageal source of hemorrhage has been excluded [ 1 ]. Results of treatment of this condition have been disapointing [ 2 ] [ 3 ]. Although some authors consider that PHG and gastric antral vascular ectasia (GAVE) represent two separate entities, a large overlap exists [ 4 ]. The use of corticosteroids has been reported to be successful in patients with GAVE [ 5 ]. On this basis, our group used oral corticosteroid therapy to treat a patient with severe PHG, who had shown no improvement from treatment with nonselective beta-blockers. A 64-year-old man with alcoholic cirrhosis was admitted for the fifth time in a 5-month period for severe anemia (Hgb, 6.1 g/dl; serum iron, 10 µg/dl), without overt gastrointestinal bleeding. An upper gastrointestinal endoscopy showed grade II esophageal varices and severe PHG of the whole stomach, which was bleeding spontaneously (Figure [ 1 ]). Antrum biopsies showed vascular ectasia without inflammatory cells and no fibromuscular hyperplasia of the lamina propria. The patient was given 2 units of packed blood cells, and treatment with oral prednisolone 20 mg/day and with oral iron was started. The patient was discharged with a regimen of 20 mg of prednisolone on alternate days. At 2 months later the hemoglobin level had risen to 10.8 g/dl, and 4 months later an upper gastrointestinal endoscopic examination showed improvement in the PHG (Figure [ 2 ]). The prednisolone dose was reduced to 15 mg on alternate days and oral iron was stopped. After 15 months, there was no evidence of gastrointestinal bleeding or anemia and the prednisolone was stopped. A third upper gastrointestinal examination showed marked improvement in the PHG (Figure [ 3 ]). Over a 3-year follow-up period there was no recurrence of anemia and the cirrhosis remained stable. Figure 1 Severe portal hypertensive gastropathy before treatment with corticosteroids Figure 2 Improvement in severe portal hypertensive gastropathy after 4 months of corticosteroid treatment Figure 3 Marked improvement in severe portal hypertensive gastropathy after 15 months of corticosteroid treatment This report seems to show the efficacy of corticosteroids in the treatment of this group of patients; however the use of this medication needs to be further evaluated in controlled studies.
- 1 February 2002
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 34 (2) , 177
Open AccessPortal Hypertensive Gastropathy: Treatment with Corticosteroids
Portal hypertensive gastropathy (PHG) has been recognised as an increasingly important source of bleeding in cirrhotic patients in whom an esophageal source of hemorrhage has been excluded [ 1 ]. Results of treatment of this condition have been disapointing [ 2 ] [ 3 ]. Although some authors consider that PHG and gastric antral vascular ectasia (GAVE) represent two separate entities, a large overlap exists [ 4 ]. The use of corticosteroids has been reported to be successful in patients with GAVE [ 5 ]. On this basis, our group used oral corticosteroid therapy to treat a patient with severe PHG, who had shown no improvement from treatment with nonselective beta-blockers. A 64-year-old man with alcoholic cirrhosis was admitted for the fifth time in a 5-month period for severe anemia (Hgb, 6.1 g/dl; serum iron, 10 µg/dl), without overt gastrointestinal bleeding. An upper gastrointestinal endoscopy showed grade II esophageal varices and severe PHG of the whole stomach, which was bleeding spontaneously (Figure [ 1 ]). Antrum biopsies showed vascular ectasia without inflammatory cells and no fibromuscular hyperplasia of the lamina propria. The patient was given 2 units of packed blood cells, and treatment with oral prednisolone 20 mg/day and with oral iron was started. The patient was discharged with a regimen of 20 mg of prednisolone on alternate days. At 2 months later the hemoglobin level had risen to 10.8 g/dl, and 4 months later an upper gastrointestinal endoscopic examination showed improvement in the PHG (Figure [ 2 ]). The prednisolone dose was reduced to 15 mg on alternate days and oral iron was stopped. After 15 months, there was no evidence of gastrointestinal bleeding or anemia and the prednisolone was stopped. A third upper gastrointestinal examination showed marked improvement in the PHG (Figure [ 3 ]). Over a 3-year follow-up period there was no recurrence of anemia and the cirrhosis remained stable. Figure 1 Severe portal hypertensive gastropathy before treatment with corticosteroids Figure 2 Improvement in severe portal hypertensive gastropathy after 4 months of corticosteroid treatment Figure 3 Marked improvement in severe portal hypertensive gastropathy after 15 months of corticosteroid treatment This report seems to show the efficacy of corticosteroids in the treatment of this group of patients; however the use of this medication needs to be further evaluated in controlled studies.